Sandoz announces a new global initiative “Act4Biosimilars”,
- Multidisciplinary steering committee set up to drive action includes patient advocacy leaders, healthcare professionals, biosimilars experts and industry leaders
- The action plan will provide a roadmap and tools to improve the approval, accessibility, acceptability and affordability (4A) of biosimilars
- Sandoz has launched an initiative to support improved healthcare access, equity and sustainability
Basel, May 31, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced the launch of a new global initiative called “Act4Biosimilars” to help address health inequalities around the world. Act4Biosimilars aims to increase patient access to breakthrough medicines by facilitating greater approval, accessibility, acceptability and affordability (the 4 A’s) of biosimilars. The initiative is supported by a multidisciplinary steering committee comprised of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase adoption of biosimilar medicines by at least 30% in more than 30 countries by 2030.
A biosimilar is a successor to a biological medicine (also called a “reference medicine”) whose patent has expired and whose exclusivity has been lost. Biosimilars match their respective reference medicine in terms of quality, safety and efficacy. Therefore, the biosimilar can be expected to behave similarly to the reference medicine in all indications and patient populations for which the reference medicines are approved. Biosimilars are used in the treatment and prevention of many debilitating and life-threatening diseases such as cancer. , psoriasis, arthritis and diabetes.
“Because of their affordability, biosimilars have opened up a new realm of possibilities for patients by allowing biologic medicines to be more widely available to those who need these advanced, life-changing treatments,” said Zorana Maravic. , CEO, Digestive Cancers Europe. “However, until we address existing inequities in access to biosimilars, far too many patients will continue to miss out on treatment with the best possible medicines.”
Act4Biosimilars.com describes the 12 objectives that were identified as part of the 4As by the steering committee to achieve the mission. These include ensuring fair pricing, involving patients in treatment decisions and streamlining the development of biosimilars.
As an immediate next step, the Steering Committee is developing an action plan to provide the strategies, tools and activities needed to equip and empower stakeholders to achieve these 12 goals, in all 30 countries and beyond. The action plan will be supported by country indicator maps to track and measure the change that is being driven by groups, associations and organizations around the world.
“While countries like Norway are leading the way in the adoption of biosimilars and have managed to achieve significant healthcare savings through increased availability of biosimilars, other countries are still making strides and aspire to reach their full potential. potential,” said Professor Emeritus Tore K Kvien, who served as head of the rheumatology department at Diakonhjemmet Hospital for 25 years. “Misinformation about the safety, efficacy and science of biosimilars continues to confuse and hinder adoption. With the Act4Biosimilars Action Plan, we will prioritize the steps needed to help better educate, inform and create actions in all countries and regions.
The steering committee will co-create the action plan with a group of biosimilar experts and key stakeholders, including patient organizations, healthcare professionals, professional associations, think tanks, government bodies and professional societies.
Act4Biosimilars is backed by founding sponsor Sandoz, a pioneer and global leader in biosimilars, which developed and brought the first biosimilar medicine to patients 16 years ago.
“Healthcare systems face more pressure than ever, which can be attributed to the costs associated with a growing and aging population, the increase in the number of people being diagnosed with chronic diseases and, more recently, the pandemic said Richard Saynor, CEO of Sandoz. “Biosimilars are part of the solution to support a more sustainable healthcare system for all and we are proud to be the founding sponsor of Act4Biosimilars, which will lead action to bring these more affordable treatment options to patients who need them. .”
Act4Biosimilars is a global initiative to increase patient access to biologic medicines by facilitating greater approval, accessibility, acceptability and affordability of biosimilars. Act4Biosimilars is led by a multidisciplinary Steering Committee comprised of patient advocacy leaders, healthcare professionals, biosimilars experts and industry leaders from around the world, with a mission to increase global adoption of biosimilars by at least 30% in more than 30 countries by 2030. Act4Biosimilars seeks to strengthen the global biosimilars movement by clearly aligning and informing action on biosimilars challenges and opportunities for patient access and sustainable healthcare and is supported by founding sponsor, Sandoz. For more information, visit Act4Biosimilars.com. Follow Act4Biosimilars on LinkedIn. Follow Act4Biosimilars on Twitter.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential”, “may”, “will”, “plans”, ” “may”, “could”, “should”, “expect”, “anticipate”, “expect”, “believe”, “commit”, “investigate”, “pipeline”, “initiate” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling of the investigational or approved products described in this press release, or regarding potential future revenues from such products. place undue reliance on these statements. These forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to important known and unknown risks and uncertainties. or more of these risks or uncertainties materialize, or if underlying assumptions prove incorrect, actual results could differ materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indication or labeling in any particular market or time. Nor can there be any guarantee that, if approved, these generic or biosimilar products will be approved for all indications included in the label of the reference product. There is also no guarantee that these products will be commercially successful in the future. In particular, our expectations regarding these products could be affected by, among other things, uncertainties inherent in research and development, including the results of clinical trials and further analysis of existing clinical data; regulatory actions or delays or government regulation generally; particular prescribing preferences of physicians and patients; competition generally, including the potential approval of additional generic or biosimilar versions of these products; global trends toward health care cost containment, including pressures from governments, payers and the general public on pricing and reimbursement and demands for increased price transparency; the results of litigation, including intellectual property litigation or other legal efforts to prevent or limit the sale of its products by Sandoz; general political, economic and business conditions, including the effects and efforts to mitigate pandemic diseases such as COVID-19; security, quality, data integrity or manufacturing issues; potential or actual breaches of data security and data privacy, or disruptions to our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F filed with the Securities and Exchange United States Commission. Novartis is providing the information in this press release as of this date and undertakes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, a division of Novartis, is a global leader in generic medicines and biosimilars. Our goal is to create pioneering access for patients by developing and commercializing innovative and affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, spanning all major therapeutic areas, accounted for $9.6 billion in sales in 2020.
Sandoz on social networks:
CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/
# # #
Novartis Media Relations
Email: [email protected]
Novartis Investor Relations
Investor Relations Central Line: +41 61 324 7944
Email: [email protected]
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
|+41 61 324 3809
+41 61 324 7188